<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Biology Structural and functional characterization of the severe fever with" exact="thrombocytopenia" post="syndrome virus L protein VogelDominik1ThorkelssonSigurdur Rafn2QueminEmmanuelle R J2MeierKristina1KoubaTomas3GogrefeNadja1BuschCarola1ReindlSophia1http://orcid.org/0000-0002-6562-0230GüntherStephan14http://orcid.org/0000-0002-9324-0796CusackStephen3GrünewaldKay2http://orcid.org/0000-0003-2986-936XRosenthalMaria1[1], Department"/>
 <result pre="emerging viruses with high epidemic potential, including Severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV). The lack of medical countermeasures, such"/>
 <result pre="to the structures of La Crosse peribunyavirus L protein and" exact="influenza" post="orthomyxovirus polymerase. Together with a comprehensive biochemical characterization of"/>
 <result pre="Marie Skłodowska-Curie 664726 iNEXT 653706 page-count: INTRODUCTION Severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV) is prevalent in East Asia and"/>
 <result pre="and functions including the viral RNA-dependent RNA polymerase (RdRp). For" exact="influenza" post="virus, another segmented negative-sense RNA virus (sNSV), small molecules"/>
 <result pre="complex have been clinically approved (5,6). However, in contrast to" exact="influenza" post="viruses, whose polymerase has been extensively investigated, structural and"/>
 <result pre="cap-snatching mechanism. This CBD is structurally similar to that of" exact="influenza" post="virus but with distinct differences in its mode of"/>
 <result pre="sequence and are denoted as the conserved promoter regions. For" exact="influenza" post="virus and LACV, the RNA 5′ end forms a"/>
 <result pre="by a prime-and-realign mechanism (13) similar to the initiation of" exact="influenza" post="virus vRNA synthesis from cRNA and Hantaan virus genome"/>
 <result pre="mM of m7GTP, m7GpppG, GTP or ATP. Thermal stability of" exact="influenza" post="A virus PB2 CBD and RVFV CBD was assessed"/>
 <result pre="and comparison with the LACV L (PDB 5AMQ) and the" exact="influenza" post="virus polymerase complex (PDB 6QCV) are shown in Supplementary"/>
 <result pre="apo-L is structurally related to LACV L and the heterotrimeric" exact="influenza" post="virus polymerase complex, although the similarity to LACV is"/>
 <result pre="the sNSV group, and the previously described structural similarity between" exact="influenza" post="virus polymerase and LACV L protein (12). Although the"/>
 <result pre="1C). The endonuclease domain (residues 1–214) is connected to an" exact="influenza" post="virus PA-C like domain via an extended linker (residues"/>
 <result pre="density in the map. According to LACV L protein and" exact="influenza" post="virus polymerase complex, we expect these unresolved regions to"/>
 <result pre="is structurally different compared to the LACV α-ribbon and the" exact="influenza" post="virus β-ribbon. In SFTSV L, the ribbon insertion is"/>
 <result pre="disordered (Figure 1B, Supplementary Figures S2–S5). The corresponding β-ribbon of" exact="influenza" post="virus, which is involved in binding of the RNA"/>
 <result pre="and involved in 5′ vRNA binding in the LACV and" exact="influenza" post="virus structures. A small part of what is presumably"/>
 <result pre="to the LACV fingernode but different from its counterpart in" exact="influenza" post="virus which has a β-hairpin insertion (Supplementary Figures S2–S4)."/>
 <result pre="and 1084–1194), which is structurally highly similar to LACV and" exact="influenza" post="virus (Figure 1, Supplementary Figures S2–S4). The palm domain"/>
 <result pre="1). Residues 1309–1402, which by analogy to the LACV and" exact="influenza" post="virus structures presumably compose the priming loop and the"/>
 <result pre="L protein has a very similar architecture as LACV and" exact="influenza" post="virus polymerase proteins with some particular differences whose functional"/>
 <result pre="and 5′ termini of the genome segments. For LACV and" exact="influenza" post="virus polymerases, distinct 3′ and 5′ RNA binding sites"/>
 <result pre="a hook-like conformation both in LACV as well as in" exact="influenza" post="virus (12,17,18). By comparing with LACV L protein bound"/>
 <result pre="the S, M and L segment promoters. Moreover, whereas in" exact="influenza" post="virus and LACV the 5′ hook structure forms within"/>
 <result pre="to RNA binding sites reported for LACV L and also" exact="influenza" post="virus polymerase. The SFTSV L protein is an active"/>
 <result pre="activating role of the 5′ end is well known for" exact="influenza" post="polymerase, and has also been described for arenaviruses, although"/>
 <result pre="either terminally and without applying a prime-and-realign mechanism similar to" exact="influenza" post="virus cRNA synthesis (22) or by priming at position"/>
 <result pre="L protein contains an active cap-binding domain In analogy to" exact="influenza" post="virus polymerase, the C-terminal region of the bunyavirus L"/>
 <result pre="for the RVFV domain but still quite high compared to" exact="influenza" post="virus PB2 CBD (KD ∼ 1.5 μM) or cellular"/>
 <result pre="Supplementary Figure S13A. (C) Thermal stability of SFTSV CBD and" exact="influenza" post="A virus PB2 CBD was tested in the presence"/>
 <result pre="SFTSV L protein that is structurally similar to RVFV and" exact="influenza" post="virus CBD, but were unable to demonstrate any cap-dependent"/>
 <result pre="in a more collapsed conformation as observed in LACV and" exact="influenza" post="virus polymerase proteins, depending on the functional state of"/>
 <result pre="the apo conformation closely resembles the LACV L protein and" exact="influenza" post="virus polymerase complex structures and, by analogy, allows prediction"/>
 <result pre="in the cryo-EM map. This has been previously observed for" exact="influenza" post="virus PB2 (61) and LACV L (12). Mechanisms for"/>
 <result pre="in combination with oseltamivir for treatment of acute uncomplicated seasonal" exact="influenza" post="A: TOPAZ trial. J. Infect. Dis.2019; 219:1026–1034.30428049 6.NoshiT., KitanoM.,"/>
 <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunit. Antiviral Res.2018; 160:109–117.30316915 7.OlschewskiS., CusackS.,"/>
 <result pre="Natl. Acad. Sci. U.S.A.2019; 116:10518–10524.31072925 17.PflugA., GuilligayD., ReichS., CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoter. Nature."/>
 <result pre="NanaoM., RuigrokR.W.et al..Structural insight into cap-snatching and RNA synthesis by" exact="influenza" post="polymerase. Nature. 2014; 516:361–366.25409151 19.GarcinD., KolakofskyD.Tacaribe arenavirus RNA synthesis"/>
 <result pre="22.DengT., VreedeF.T., BrownleeG.G.Different de novo initiation strategies are used by" exact="influenza" post="virus RNA polymerase on its cRNA and viral RNA"/>
 <result pre="LeeW.J.Molecular genomic characterization of tick- and human-derived severe fever with" exact="thrombocytopenia" post="syndrome virus isolates from South Korea. PLoS Negl. Trop."/>
 <result pre="ZhangS.Y., LiuY., LiJ.D., SunY.L., ZhangL., ZhangQ.F., PopovV.L., LiC.et al..Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
 <result pre="LiA., LiangM., LiD., ElliottR.M.Reverse genetics system for severe fever with" exact="thrombocytopenia" post="syndrome virus. J. Virol.2015; 89:3026–3037.25552716 52.ZhongW., UssA.S., FerrariE., LauJ.Y.,"/>
 <result pre="UssA.S., FerrariE., LauJ.Y., HongZ.De novo initiation of RNA synthesis by" exact="hepatitis" post="C virus nonstructural protein 5B polymerase. J. Virol.2000; 74:2017–2022.10644375"/>
 <result pre="J. Virol.2018; 92:e01414-17.29046442 56.Te VelthuisA.J.W., OymansJ.Initiation, elongation and realignment during" exact="influenza" post="virus mRNA synthesis. J. Virol.2017; 92:e01775-17. 57.JinH., ElliottR.M.Non-viral sequences"/>
 <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunit. Antimicrob. Agents Chemother.2015; 59:1569–1582.25547360 61.ThierryE.,"/>
</results>
